Lexeo Therapeutics (LXEO) Total Liabilities (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Total Liabilities data on file, last reported at $18.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 49.81% year-over-year to $18.9 million; the trailing twelve-month figure through Mar 2026 stood at $18.9 million (down 49.81% YoY), and the FY2025 full-year result was $22.0 million, down 26.85% from the prior year.
• Total Liabilities slipped to $18.9 million in Q1 2026, from $22.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $37.8 million in Q2 2025 to a low of $18.9 million in Q1 2026.
• A 5-year average of $28.8 million and a median of $28.6 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 39.88% in 2025 and plunged 49.81% in 2026, its largest moves.
• Tracing LXEO's Total Liabilities over 5 years: stood at $25.0 million in 2022, then gained by 5.1% to $26.3 million in 2023, then climbed by 14.57% to $30.1 million in 2024, then slipped by 26.85% to $22.0 million in 2025, then fell by 14.35% to $18.9 million in 2026.
• Business Quant data shows LXEO's Total Liabilities at $18.9 million in Q1 2026, $22.0 million in Q4 2025, and $23.0 million in Q3 2025.